5676 related articles for article (PubMed ID: 3167614)
1. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
Berd D; Mastrangelo MJ
Cancer Invest; 1988; 6(3):337-49. PubMed ID: 3167614
[TBL] [Abstract][Full Text] [Related]
2. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.
Berd D; Maguire HC; McCue P; Mastrangelo MJ
J Clin Oncol; 1990 Nov; 8(11):1858-67. PubMed ID: 2230873
[TBL] [Abstract][Full Text] [Related]
3. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.
Berd D; Maguire HC; Mastrangelo MJ
Cancer Res; 1986 May; 46(5):2572-7. PubMed ID: 3697996
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.
Berd D; Sato T; Cohn H; Maguire HC; Mastrangelo MJ
Int J Cancer; 2001 Nov; 94(4):531-9. PubMed ID: 11745440
[TBL] [Abstract][Full Text] [Related]
5. Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.
Berd D; Sato T; Mastrangelo MJ
Cancer Immunol Immunother; 2002 Aug; 51(6):320-6. PubMed ID: 12111120
[TBL] [Abstract][Full Text] [Related]
6. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine.
Hsueh EC; Gupta RK; Qi K; Morton DL
J Clin Oncol; 1998 Sep; 16(9):2913-20. PubMed ID: 9738558
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
8. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.
Berd D; Sato T; Maguire HC; Kairys J; Mastrangelo MJ
J Clin Oncol; 2004 Feb; 22(3):403-15. PubMed ID: 14691123
[TBL] [Abstract][Full Text] [Related]
9. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
10. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
Oratz R; Dugan M; Roses DF; Harris MN; Speyer JL; Hochster H; Weissman J; Henn M; Bystryn JC
Cancer Res; 1991 Jul; 51(14):3643-7. PubMed ID: 2065322
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide.
Elias EG; Suter CM; Fabian DS
J Surg Oncol; 1997 Jan; 64(1):17-22. PubMed ID: 9040795
[TBL] [Abstract][Full Text] [Related]
12. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; LiƩnard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
13. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
Lieberman R; Wybran J; Epstein W
Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
[TBL] [Abstract][Full Text] [Related]
14. Active-specific immunotherapy for melanoma.
Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L
J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701
[TBL] [Abstract][Full Text] [Related]
15. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
Hsueh EC; Essner R; Foshag LJ; Ollila DW; Gammon G; O'Day SJ; Boasberg PD; Stern SL; Ye X; Morton DL
J Clin Oncol; 2002 Dec; 20(23):4549-54. PubMed ID: 12454111
[TBL] [Abstract][Full Text] [Related]
16. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma.
Bystryn JC; Oratz R; Roses D; Harris M; Henn M; Lew R
Cancer; 1992 Mar; 69(5):1157-64. PubMed ID: 1739915
[TBL] [Abstract][Full Text] [Related]
17. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.
Jones RC; Kelley M; Gupta RK; Nizze JA; Yee R; Leopoldo Z; Qi K; Stern S; Morton DL
Ann Surg Oncol; 1996 Sep; 3(5):437-45. PubMed ID: 8876885
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma.
Dillman RO; Nayak SK; Barth NM; DeLeon C; Schwartzberg LS; Spitler LE; Church C; O'Connor AA; Beutel LD
Cancer Biother Radiopharm; 1998 Jun; 13(3):165-76. PubMed ID: 10850352
[TBL] [Abstract][Full Text] [Related]
19. Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients.
Baars A; Claessen AM; van den Eertwegh AJ; Gall HE; Stam AG; Meijer S; Giaccone G; Meijer CJ; Scheper RJ; Wagstaff J; Vermorken JB; Pinedo HM
Ann Oncol; 2000 Aug; 11(8):965-70. PubMed ID: 11038032
[TBL] [Abstract][Full Text] [Related]
20. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.
Berd D; Mastrangelo MJ
Cancer Res; 1988 Mar; 48(6):1671-5. PubMed ID: 2830969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]